USP7 (Ubiquitin-Specific Peptidase 7) antibodies are critical tools for studying deubiquitination processes in diseases such as cancer and neurodegeneration.
| Antibody | CAB13565 (Assay Genie) | ab272079 (Abcam) | A01239 (Boster Bio) |
|---|---|---|---|
| Host Species | Rabbit | Rabbit | Rabbit |
| Reactivity | Human, Mouse, Rat | Human, Mouse | Human, Mouse, Rat |
| Applications | WB, IHC-P, ELISA | WB, IP, IHC | WB, IHC, Flow Cytometry |
| Immunogen | Recombinant protein (AA 206-1102) | Recombinant full-length protein | Recombinant protein (AA 100-200) |
| Observed MW | 138 kDa | 128 kDa | 128 kDa (predicted) |
USP7 regulates tumor suppressors like p53 by counteracting ubiquitin ligases (e.g., HDM2) .
Antibodies such as CAB13565 show high specificity in detecting USP7 across cell lines (MCF7, HeLa) .
Monoclonal antibodies like COV2-2130 and COV2-2196 have demonstrated efficacy in neutralizing SARS-CoV-2 by targeting the spike protein:
| Antibody | COV2-2130 | COV2-2196 |
|---|---|---|
| Target | Spike protein (non-overlapping epitopes) | Spike protein (RBD) |
| In Vivo Efficacy | Reduces viral load in mice | Protects macaques from infection |
| Clinical Relevance | Licensed by AstraZeneca | In preclinical trials |